All In Biotech

Drug Trial Radar · NCT07590934

Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

A Phase Ib/II, Open-label, Multi-centre, Platform Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Multiple Anti-Cancer Agents in Metastatic Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 152 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

152

Planned (sponsor's estimate)

Start

Jun 3, 2026

Primary completion

Sep 25, 2029

Study completion Sep 25, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
May 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.

Conditions

  • Metastatic Prostate Cancer

Interventions

  • AZD2265 (FPI-2265)Drug

    AZD2265 (FPI-2265) will be administered as an intravenous (IV) injection.

  • Palacaparib (AZD9574)Drug

    Palacaparib (AZD9574) will be administered orally.

  • DocetaxelDrug

    Docetaxel will be administered as an IV infusion.

  • AZD2287 (Imaging agent)Drug

    AZD2287 will be administered as an IV injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of participants with treatment-emergent adverse events (TEAEs)including serious adverse events (SAEs), treatment-related AEs (TRAEs) and adverse events of special interests (AESIs)Time frame: Up to approximately 1 year after last dose
  2. Part A: Number of participants with dose limiting toxicities (DLTs)Time frame: From date of first dose up to approximately 2 cycles (up to 3 months)
  3. Part B: Number of participants with TEAEsTime frame: Up to approximately 1 year after last dose
  4. Part B: Prostate Specific Antigen 50 (PSA50) response rateTime frame: Up to 3 years 4 months

Locations

38 sites in 7 countries. Site status is shown where the registry gives one.

  • Research Site

    Duarte, California · Not yet recruiting

  • Research Site

    Encino, California · Not yet recruiting

  • Research Site

    South Pasadena, California · Recruiting

  • Research Site

    Miami, Florida · Recruiting

  • Research Site

    Orlando, Florida · Not yet recruiting

  • Research Site

    Tampa, Florida · Not yet recruiting

  • Research Site

    Metairie, Louisiana · Not yet recruiting

  • Research Site

    Minneapolis, Minnesota · Not yet recruiting

  • Research Site

    Omaha, Nebraska · Recruiting

  • Research Site

    New York, New York · Not yet recruiting

  • Research Site

    Portland, Oregon · Not yet recruiting

  • Research Site

    Houston, Texas · Not yet recruiting

  • Research Site

    North Adelaide, Australia · Not yet recruiting

  • Research Site

    Essen, Germany · Not yet recruiting

  • Research Site

    Jena, Germany · Not yet recruiting

  • Research Site

    Rostock, Germany · Not yet recruiting

  • Research Site

    Tübingen, Germany · Not yet recruiting

  • Research Site

    Bergamo, Italy · Not yet recruiting

  • Research Site

    Meldola, Italy · Not yet recruiting

  • Research Site

    Milan, Italy · Not yet recruiting

  • Research Site

    Milan, Italy · Not yet recruiting

  • Research Site

    Roma, Italy · Not yet recruiting

  • Research Site

    Seoul, South Korea · Not yet recruiting

  • Research Site

    Seoul, South Korea · Not yet recruiting

  • Research Site

    Seoul, South Korea · Not yet recruiting

  • Research Site

    Seoul, South Korea · Not yet recruiting

  • Research Site

    Seoul, South Korea · Withdrawn

  • Research Site

    Barcelona, Spain · Not yet recruiting

  • Research Site

    L'Hospitalet de Llobregat, Spain · Not yet recruiting

  • Research Site

    Madrid, Spain · Not yet recruiting

  • Research Site

    Madrid, Spain · Not yet recruiting

  • Research Site

    Pamplona, Spain · Not yet recruiting

  • Research Site

    Belfast, United Kingdom · Not yet recruiting

  • Research Site

    Fulham, United Kingdom · Not yet recruiting

  • Research Site

    Guildford, United Kingdom · Not yet recruiting

  • Research Site

    London, United Kingdom · Not yet recruiting

  • Research Site

    Newcastle upon Tyne, United Kingdom · Not yet recruiting

  • Research Site

    Oxford, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.